A Multicenter Open-label Phase 1/1b Study to Evaluate Safety, Feasibility and Early Treatment Effect of Padeliporfin VTP Using Robotic Assisted Bronchoscopy and Cone Beam CT Guidance in Patients With Peripheral Lung Cancer

Phase 1/1b, safety, feasibility, and light dose titration study followed by further study of therapeutic ablation effects.
Patients with high risk of peripheral primary lung cancer, stage 1A1/1A2, for whom surgical treatment is planned, will be recruited. Surgery will be performed at 5-21 days following the VTP procedure.
Study intervention: robotic assisted bronchoscopic Padeliporfin VTP lung ablation: vascular targeted photodynamic therapy using Padeliporfin photosensitizer.

Start Date28 May 2025

Sponsor / Collaborator

IMPACT Biotech Ltd

NCT05919238

/ RecruitingPhase 1

A Multicenter Open-label Phase 1 Trial to Evaluate Safety and Preliminary Efficacy of Endovascularly Applied Vascular Targeted Photodynamic Therapy (VTP) for Patients With Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma

This is a prospective, multicenter, non-randomized, open label light dose escalation phase I trial to evaluate the safety and preliminary efficacy of Padeliporfin vascular targeted photodynamic therapy (VTP) applied via endovascular fiber placement within a dilatation catheter, through the superior mesenteric artery (SMA) in patients with stage III, locally advanced (LA) unresectable pancreatic ductal adenocarcinoma (PDAC). The investigators will evaluate safety and preliminary efficacy of Padeliporfin VTP administered endovascularly using light dose escalation.

Start Date15 May 2024

Sponsor / Collaborator

IMPACT Biotech Ltd

NCT04620239

/ RecruitingPhase 3

Multicenter Phase 3 Pivotal Study to Evaluate the Safety and Efficacy of TOOKAD (Padeliporfin) Vascular Targeted Photodynamic Therapy in the Treatment of Low Grade Upper Tract Urothelial Cancer

This is a phase 3, open label, single arm study of padeliporfin in the treatment of Upper Tract Urothelial Carcinoma (UTUC). The ENLIGHTED study will recruit patients with low-grade non-invasive upper tract urothelial carcinoma in either the kidney or the ureter. Patients will be treated with padeliporfin VTP in two phases: an Induction Treatment Phase and a Maintenance Treatment Phase and will be followed up for up to an additional 48 months in the long term (non intervention) follow up phase with the specific duration depending on the patient's response to treatment

Start Date22 Mar 2021

Sponsor / Collaborator

Steba Biotech NV

[+2]

100 Clinical Results associated with Padeliporfin

100 Translational Medicine associated with Padeliporfin

100 Patents (Medical) associated with Padeliporfin

Literatures (Medical) associated with Padeliporfin

30 Jan 2025·INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE

Proteomics Reveals Mechanisms of Delayed Keratoconus Progression: A Study of Corneas Following Two Light-Activated Crosslinking Treatments

Article

Author: Mohren, Ronny ; Marcovich, Arie L. ; Scherz, Avigdor ; Brandis, Alexander ; Vogels, Demi H. J. ; LaPointe, Vanessa L. S. ; Dickman, Mor M. ; Cillero-Pastor, Berta ; Brekelmans, Jurriaan ; Vos, Naomi R. N.

Purpose:

This study aims to elucidate on changes in biological pathways in rabbit corneas induced by two methods of light-activated corneal stiffening: topical application of riboflavin with dextran (RF-D) or WST11 with dextran (WST-D) followed by ultraviolet A (UVA) or near-infrared (NIR) illumination, respectively.

Methods:

Rabbit corneas were mechanically de-epithelialized, then left untreated (N = 3) or treated with either RF-D/UVA (N = 3) or WST-D/NIR (N = 3). After one week, quantitative proteomics was performed on untreated, RF-D/UVA- and WST-D/NIR-treated corneas. Pathway enrichment analysis was performed to identify the biological processes associated with the treatments. To identify the abundance and spatial distribution of lipids in the untreated, WST-D/NIR- and RF-D/UVA-treated corneal stroma, lipid mass spectrometry imaging was performed together with hematoxylin and eosin staining.

Results:

Between RF-D/UVA- and WST-D/NIR-treated corneas, 37 and 39 proteins, respectively, were differentially expressed compared to untreated corneas (P < 0.05). Pathway enrichment analysis showed the effect of RF-D/UVA treatment on cell metabolism and terminal differentiation of keratocytes, while WST-D/NIR modified extracellular matrix regulation and the mitogen-activated protein kinase signaling cascade. When comparing the RF-D/UVA and WST-D/NIR treatment, 74 proteins were differentially expressed, affecting cellular metabolism and respiration, complement activation, the activation of matrix metalloproteinases, and lipoprotein metabolism. The lipid profile for the RF-D/UVA- and WST-D/NIR-treated stromas were similar, whereas differences were observed comparing both treatments to untreated corneal stroma.

Conclusions:

Proteomics indicated a metabolic shift from oxidative phosphorylation to glycolysis and hypoxia after RF-D/UVA treatment. In contrast, WST-D/NIR stiffening maintained normal respiration and involved extracellular matrix remodeling.

30 Sep 2023·Translational andrology and urology

Advances in chemoablation in upper tract urothelial carcinoma: overview of indications and treatment patterns.

Review

Author: Gottlieb, Josh ; Linehan, Jennifer ; Murray, Katie S

Localized upper tract urothelial carcinoma (UTUC) is a difficult disease for clinicians to treat, due to the multitude of oncological and patient factors to consider. Despite the challenges of diagnostic staging, endoscopic management, and disease recurrence, there is still a need for local therapeutic options that do not subject patients to the morbidities of radical nephroureterectomy (RNU). Intraluminal chemotherapies have allowed for improved oncological control in patients with low-grade disease receiving renal-sparing treatment approaches. This narrative review discusses the treatment modalities available for localized low-grade UTUC, with a focus on the current status of chemoablation. The OLYMPUS trial was a pivotal study that lead to the Food and Drug Administration (FDA) approval of UGN-101 (mitomycin-C) in April 2020 for the treatment of low-grade UTUC, and intraluminal chemotherapy is now a widely used modality for managing this disease. The trial reported a complete response (CR) rate of 59%, and an estimated treatment durability of 82% at 1 year. However, a concern was the reported 44% ureteral stricture rate using the retrograde approach. More research is currently underway to determine the ideal instillation method for intraluminal therapies (e.g., retrograde vs. antegrade). Lastly, we discuss upcoming treatment options. Newer novel agents like padeliporfin vascular targeted photodynamic (VTP) therapy (brand name TOOKAD) are currently being studied, which will in hope provide additional treatment options for UTUC patients.

01 May 2023·The Journal of urology

Final Results of a Phase I Trial of WST-11 (TOOKAD Soluble) Vascular-targeted Photodynamic Therapy for Upper Tract Urothelial Carcinoma

Article

Author: Lin, Oscar ; Tracey, Andrew T. ; Nogueira, Lucas M. ; Dalbagni, Guido ; Sjoberg, Daniel D. ; Alvim, Ricardo G. ; Pietzak, Eugene J. ; Solit, David B. ; Benfante, Nicole E. ; Demac, Quinlan ; Donat, S. Machele ; Bochner, Bernard H. ; Hakimi, A. Ari ; Reisz, Peter A. ; Yip, Wesley ; Kim, Kwanghee ; Al-Ahmadie, Hikmat ; Vanden Berg, Rand W. ; Scherz, Avigdor ; Coleman, Jonathan A. ; Bajorin, Dean F.

PURPOSE:

Vascular-targeted photodynamic therapy with the intravascular photosensitizing agent padeliporfin (WST-11/TOOKAD-Soluble) has demonstrated therapeutic efficacy as an ablative treatment for localized cancer with potential adaptation for endoscopic management of upper tract urothelial carcinoma. This Phase I trial (NCT03617003) evaluated the safety of vascular-targeted photodynamic therapy with WST-11 in upper tract urothelial carcinoma.

MATERIALS AND METHODS:

Nineteen patients underwent up to 2 endoscopic vascular-targeted photodynamic therapy treatments, with follow-up for up to 6 months. Patients who had residual or recurrent upper tract urothelial carcinoma (any grade/size) failing prior endoscopic treatment or unable or unwilling to undergo surgical resection were eligible for inclusion. The primary endpoint was to identify the maximally tolerated dose of laser light fluence. A dose escalation model was employed, with increasing light fluence (100-200 mW/cm) using a modified continual reassessment method. The secondary endpoint was treatment efficacy, defined by absence of visible tumor and negative urine cytology 30 days posttreatment.

RESULTS:

Fourteen (74%) patients received the maximally tolerated dose of 200 mW/cm, 2 (11%) of whom experienced a dose-limiting toxicity. The initial 30-day treatment response rate was 94% (50% complete, 44% partial). Eight patients underwent a second treatment, with a final observed 68% complete response rate. Leading toxicities were flank pain (79%) and hematuria (84%), which were transient. No ureteral strictures associated with treatment were identified during follow-up.

CONCLUSIONS:

Vascular-targeted photodynamic therapy with WST-11 has an acceptable safety profile with strong potential as an effective, kidney-sparing endoscopic management option for upper tract urothelial carcinoma. The recently initiated multicenter Phase 3 ENLIGHTED trial (NCT04620239) is expected to provide further evidence on this therapy.

News (Medical) associated with Padeliporfin

04 Dec 2024

·www.globenewswire.com

ImPact Biotech Presents Updated Interim Phase 3 Data from ENLIGHTED Study of Padeliporfin VTP in Low Grade UTUC at SUO 2024

-- Complete response (CR) observed in 85% (17/20) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed the Induction Treatment Phase -- -- Padeliporfin VTP treatment continues to be safe and efficacious, establishing profile consistent with prior results alongside additional follow-up in Maintenance Treatment Phase – TEL AVIV, Israel, Dec. 04, 2024 (GLOBE NEWSWIRE) -- ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporfin vascular targeted photodynamic (VTP) therapy to treat a range of solid tumors, today announced updated interim results from ENLIGHTED, the Company’s ongoing Phase 3 study of Padeliporfin VTP treatment in patients with low-grade upper tract urothelial cancer (UTUC). These data will be presented at the 25th Annual Meeting of the Society of Urologic Oncology (SUO 2024) taking place December 4-6, 2024 in Dallas, Texas. “As data from the ENLIGHTED trial matures, we continue to be encouraged by compelling and sustained efficacy signals from treatment with Padeliporfin VTP,” said Eyal Morag, M.D., Chief Medical Officer of ImPact Biotech. “These results further underscore the potential for Padeliporfin VTP to transform the treatment paradigm in low-grade UTUC, offering efficacy in line with standard of care but without the associated risk of organ injury or loss. We look forward to sharing additional data from the ENLIGHTED trial and to progressing Padeliporfin VTP in other unresectable solid tumors in 2025.” As of July 22, 2024, the data cut-off for the poster presentation at SUO, 32 patients had begun treatment, of which 20 had completed ITP and were evaluable for efficacy. Key updated preliminary results from the Phase 3 ENLIGHTED study of Padeliporfin VTP: Clinical Profile: 17 of the 20 (85%) response-evaluable patients achieved a CR at the end of ITP. Safety and Tolerability Profile: Padeliporfin VTP was well-tolerated with a safety profile consistent with the previous data obtained from the Phase 1 study and previously announced preliminary Phase 3 results. Adverse events (AEs) observed were primarily Grade 1 or 2, most of which were pain related, and all resolved within two to seven days. Only one patient experienced a Grade 3 serious adverse event that was related to the VTP therapy, which resolved within two days.There were no Grade 4 or 5 serious adverse events observed. ImPact continues to recruit for the ENLIGHTED study. As previously announced in September, the Company has exceeded 50% enrollment in the study and expects to complete enrollment by early 2025. Poster & Session Details: Poster Title: Efficacy and Safety of Padeliporfin Vascular Targeted Photodynamic Therapy (VTP) for Treatment of Low-grade Upper Tract Urothelial Cancer (LG UTUC): ENLIGHTENED Phase 3 studyPresenter: Vitaly Margulis, M.D., Chair in Urology, UT Southwestern Medical CenterPoster Number: 244Session Title: SUO24 Networking and Abstract Discussion SessionSession Date & Time: December 6, 2024, 1:45 PM CST About ENLIGHTEDThe Phase 3 ENLIGHTED study is a single arm, non-randomized, open-label, pivotal trial evaluating Padeliporfin VTP for the treatment of low-grade UTUC. Across 29 clinical sites globally, ImPact is targeting enrollment of up to 100 patients with new or recurrent low-grade, non-invasive UTUC of the kidney or ureter. The study consists of two parts – an Induction Treatment Phase (ITP) and Maintenance Treatment Phase (MTP) – across which Padeliporfin, a photosensitizing drug, is administered intravenously and VTP therapy is performed, via an outpatient endoscopy which applies a laser fiber illumination for 10 minutes in the proximity of the tumor, leading to local activation of Padeliporfin in the tumor. ITP consists of one-to-three treatments with VTP therapy at four-week intervals or until a complete response (CR) is achieved; MTP follows with standard-of-care treatment alongside VTP therapy administered every three months for up to 12 months. The study’s primary objective is to assess the response rate to Padeliporfin VTP treatment at the end of ITP, with secondary objectives evaluating safety, tolerability and duration of response. About ImPact Biotech ImPact Biotech is an advanced clinical-stage oncology company focused on the development and commercialization of Padeliporfin Vascular Targeted Photodynamic (VTP) therapy, a minimally invasive drug-device combination for selective ablation of unresectable solid tumors. The novel VTP platform delivers non-thermal laser light via optical fibers to locally activate Padeliporfin in the tumor microenvironment. Padeliporfin VTP is currently being evaluated in a pivotal Phase 3 study in low-grade upper tract urothelial carcinoma (UTUC) with earlier stage studies ongoing or planned in high-grade UTUC, pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). The Company has longstanding collaborations with the Weizmann Institute of Science and Memorial Sloan Kettering Cancer Center and operations in the EU, Israel and the US. For more on ImPact Biotech Ltd., visit: www.impactbiotech.com and the ENLIGHTED clinical trial website (for the US): https://www.enlighted-study.com. Contacts Global Head of Business DevelopmentGuy Schmidtguy.schmidt@impactbiotech.com Precision AQJosh Rappaportjosh.rappaport@precisionaq.com

Phase 3Clinical ResultASCOPhase 1

07 Nov 2024

·www.globenewswire.com

ImPact Biotech Presents Updated Interim Phase 3 Data from ENLIGHTED Study of Padeliporfin VTP in Low Grade UTUC at EMUC 2024

-- Complete response (CR) observed in 86% (12/14) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed the Induction Treatment Phase -- -- Padeliporfin VTP treatment continues to be safe and efficacious, establishing profile consistent with prior results alongside additional follow-up in Maintenance Treatment Phase -- TEL AVIV, Israel, Nov. 07, 2024 (GLOBE NEWSWIRE) -- ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporfin vascular targeted photodynamic (VTP) therapy to treat a range of solid tumors, today announced updated interim results from ENLIGHTED, the Company’s ongoing Phase 3 study of Padeliporfin VTP treatment in patients with low-grade upper tract urothelial cancer (UTUC), at the 16th European Multidisciplinary Congress on Urological Cancers (EMUC 2024) taking place in Lisbon, Portugal. “The overall profile and robustness of response to Padeliporfin VTP underscores its potential to reshape the therapeutic landscape in patients with UTUC,” said Gautier Marcq, M.D., Assistant Professor Urology Department, Centre de Universitaire Régional Hospitalier de Lille, Lille, France and an investigator in the ENLIGHTED study. “Current standards of care in this indication often require an invasive surgical intervention, resulting in many cases in organ injury or loss, or a burdensome therapeutic regimen that fails to match surgery in efficacy. These results highlight Padeliporfin VTP as a compelling alternative, which may not require patients to compromise between sparing their organs and treating their cancer. I am encouraged by these data and look forward to additional analyses towards improved treatment and better outcomes for patients with UTUC.” The Phase 3 ENLIGHTED study is a single arm, non-randomized, open-label, pivotal trial evaluating Padeliporfin VTP for the treatment of low-grade UTUC. Across 29 clinical sites globally, ImPact is targeting enrollment of up to 100 patients with new or recurrent low-grade, non-invasive UTUC of the kidney or ureter. The study consists of two parts – an Induction Treatment Phase (ITP) and Maintenance Treatment Phase (MTP) – across which Padeliporfin, a photosensitizing drug, is administered intravenously and VTP therapy is performed, via an outpatient endoscopy which applies a laser fiber illumination for 10 minutes in the proximity of the tumor, leading to local activation of Padeliporfin in the tumor. ITP consists of one-to-three treatments with VTP therapy at four-week intervals or until a complete response (CR) is achieved; MTP follows with standard-of-care treatment alongside VTP therapy administered every three months for up to 12 months. The study’s primary objective is to assess the response rate to Padeliporfin VTP treatment at the end of ITP, with secondary objectives evaluating safety, tolerability and duration of response. As of April 29, 2024, the data cut-off for this presentation, 22 patients had begun treatment, of which 14 had completed ITP and were evaluable for efficacy. Key updated preliminary results from the Phase 3 ENLIGHTED study of Padeliporfin VTP: Clinical Profile: Twelve of the 14 (86%) response-evaluable patients achieved a CR at the end of ITP. Safety and Tolerability Profile: Padeliporfin VTP was well-tolerated with a safety profile consistent with the previous data obtained from the Phase 1 study and previously announced preliminary Phase 3 results. Adverse events (AEs) observed were primarily Grade 1 or 2, most of which were pain related, and all resolved within two to seven days. Only one patient experienced a Grade 3 serious adverse event that was related to the VTP therapy, which resolved within two days.There were no Grade 4 or 5 serious adverse events observed. “We are highly encouraged to see consistent patient responses to Padeliporfin VTP treatment as we progress the ENLIGHTED Phase 3 study,” said Eyal Morag, M.D., Chief Medical Officer of ImPact Biotech. “This expansion of our dataset presented in June further establishes the potential for Padeliporfin VTP to transform the treatment landscape for UTUC, by providing efficacy in line with standard of care without incurring risk of organ injury or loss. With trial enrollment on track to conclude by early 2025, we look forward to providing subsequent data updates that we expect to provide basis for registration of Padeliporfin VTP in low grade UTUC. In parallel, we will look to replicate this effect in other unresectable solid tumors, beginning with our planned Phase 1 study in PDAC.” ImPact continues to recruit for the ENLIGHTED study. As previously announced in September, the Company has exceeded 50% enrollment in the study and expects to complete enrollment by early 2025. The poster will be viewable during the EMUC24 Networking and Abstract Discussion Session on Saturday, November 9, 2024, 17:30 GMT. About ImPact Biotech ImPact Biotech is an advanced clinical-stage oncology company focused on the development and commercialization of Padeliporfin Vascular Targeted Photodynamic (VTP) therapy, a minimally invasive drug-device combination for selective ablation of unresectable solid tumors. The novel VTP platform delivers non-thermal laser light via optical fibers to locally activate Padeliporfin in the tumor microenvironment. Padeliporfin VTP is currently being evaluated in a pivotal Phase 3 study in low-grade upper tract urothelial carcinoma (UTUC) with earlier stage studies ongoing or planned in high-grade UTUC, pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). The Company has longstanding collaborations with the Weizmann Institute of Science and Memorial Sloan Kettering Cancer Center and operations in the EU, Israel and the US. For more on ImPact Biotech Ltd., visit: www.impactbiotech.com and the ENLIGHTED clinical trial website (for the US): https://www.enlighted-study.com. Contacts Global Head of Business DevelopmentGuy Schmidtguy.schmidt@impactbiotech.com Precision AQJosh Rappaportjosh.rappaport@precisionaq.com

Phase 3Clinical ResultPhase 1

25 Oct 2024

·www.biospace.com

ImPact Biotech to Present Updated Interim Phase 3 Data from ENLIGHTED Study of Padeliporfin VTP in Low Grade UTUC at EMUC 2024

TEL AVIV, Israel, Oct. 25, 2024 (GLOBE NEWSWIRE) -- ImPact Biotech, a clinical-stage biotechnology company focused on developing Padeliporfin vascular targeted photodynamic (VTP) therapy to treat a range of solid tumors, today announced an abstract including interim results from ENLIGHTED, the Company’s ongoing Phase 3 study of Padeliporfin VTP treatment of patients with low-grade upper tract urothelial cancer (UTUC), will be presented at the 16 th European Multidisciplinary Congress on Urological Cancers (EMUC 2024) taking place November 7 – 10, 2024, in Lisbon, Portugal. Poster & Session Details: Poster Title: ENLIGHTED Phase 3 study: Efficacy and Safety of Padeliporfin Vascular Targeted Photodynamic Therapy (VTP) for Treatment of Low-grade Upper Tract Urothelial Cancer (LG UTUC) Presenter: Gautier Marcq, M.D., M.Sc. Poster Number: P225 Session Title: EMUC24 Networking and Abstract Discussion Session Session Date & Time: November 9, 2024, 17:30 GMT About ImPact Biotech ImPact Biotech is an advanced clinical-stage oncology company focused on the development and commercialization of Padeliporfin Vascular Targeted Photodynamic (VTP) therapy, a minimally invasive drug-device combination for selective ablation of unresectable solid tumors. The novel VTP platform delivers non-thermal laser light via optical fibers to locally activate Padeliporfin in the tumor microenvironment. Padeliporfin VTP is currently being evaluated in a pivotal Phase 3 study in low-grade upper tract urothelial carcinoma (UTUC) with earlier stage studies ongoing or planned in high-grade UTUC, pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). The Company has longstanding collaborations with the Weizmann Institute of Science and Memorial Sloan Kettering Cancer Center and operations in the EU, Israel and the US. For more on ImPact Biotech Ltd., visit: and the ENLIGHTED clinical trial website (for the US): . Contacts Global Head of Business Development Guy Schmidt guy.schmidt@impactbiotech.com Precision AQ Josh Rappaport josh.rappaport@precisionaq.com

Phase 3

100 Deals associated with Padeliporfin

External Link

KEGG	Wiki	ATC	Drug Bank
-	Padeliporfin	L01XD07	DB15575

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Adenocarcinoma of prostate	EU	Steba Biotech NV	10 Nov 2017
Adenocarcinoma of prostate	IS	Steba Biotech NV	10 Nov 2017
Adenocarcinoma of prostate	LI	Steba Biotech NV	10 Nov 2017
Adenocarcinoma of prostate	NO	Steba Biotech NV	10 Nov 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Renal Pelvis and Ureter Urothelial Carcinoma	Phase 3	US	Steba Biotech NV	22 Mar 2021
Renal Pelvis and Ureter Urothelial Carcinoma	Phase 3	AT	Steba Biotech NV	22 Mar 2021
Renal Pelvis and Ureter Urothelial Carcinoma	Phase 3	FR	Steba Biotech NV	22 Mar 2021
Renal Pelvis and Ureter Urothelial Carcinoma	Phase 3	DE	Steba Biotech NV	22 Mar 2021
Renal Pelvis and Ureter Urothelial Carcinoma	Phase 3	IL	Steba Biotech NV	22 Mar 2021
Renal Pelvis and Ureter Urothelial Carcinoma	Phase 3	ES	Steba Biotech NV	22 Mar 2021
Transitional cell cancer of the renal pelvis and ureter recurrent	Phase 3	US	Steba Biotech NV	22 Mar 2021
Transitional cell cancer of the renal pelvis and ureter recurrent	Phase 3	AT	Steba Biotech NV	22 Mar 2021
Transitional cell cancer of the renal pelvis and ureter recurrent	Phase 3	FR	Steba Biotech NV	22 Mar 2021
Transitional cell cancer of the renal pelvis and ureter recurrent	Phase 3	DE	Steba Biotech NV	22 Mar 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04620239 (ENLIGHTED, GlobeNewswire) Manual	Phase 3	Renal Pelvis and Ureter Urothelial Carcinoma	20	Padeliporfin VTP	uckwnziefq(kubwtuqyko) = excdqlnfyi mjjahkniqa (zcnplccrlv )	Positive	04 Dec 2024
NCT04620239 (UCM301 \| ENLIGHTED, GlobeNewswire) Manual	Phase 3	Renal Pelvis and Ureter Urothelial Carcinoma	14	Padeliporfin VTP	yfhlrtrdte(dscgurjoqq) = azjxyittcb yeokvgpcsc (alihmyyydp )	Positive	07 Nov 2024
NCT04620239 (ENLIGHTED, Biospace) Manual	Phase 3	Renal Pelvis and Ureter Urothelial Carcinoma	13	Padeliporfin	fssmwxfsgp(oqexbnipte) = tzgoylwret nwoqleqzir (mkffpvjimv ) View more	Positive	02 Jun 2024
NCT04620239 (ENLIGHTED, Biospace) Manual	Phase 3	Transitional Cell Carcinoma	9	Padeliporfin	hnyvcnrtac(tgzdyxvflf) = txapzppjty cwgwlzajwy (nzakfqzxxg )	Positive	06 May 2024
NCT03315754 (CTgov)	Phase 2	Localized Prostate Carcinoma	50	TOOKAD Soluble 4 mg/kg	ifsnravjjt(rkqygfvmwj) = eterwtepae rmaucwbnjk (gogzfdcoqg, rsksgjvnhc - bpcbwsplxq) View more	-	02 Aug 2023
NCT03315754 (ASCO 12021 \| ASCO 22021) Manual	Phase 2	Prostatic Cancer	46	padeliporfin	raxnsmbtdr(dfqvfjparv) = dvruingtyc kflcpamnac (sqrnngahsk ) View more	Positive	28 May 2021
NCT03617003 (ASCO_GU2021) Manual	Phase 1	Renal Pelvis and Ureter Urothelial Carcinoma	14	phototherapy +WST11	ffqibykzcg(wlkddqxatl) = fkefgxsnfw guhifmdlrd (lbygbxcxow ) View more	Positive	20 Feb 2021
NCT01310894 (CLIN1001 PCM301, Pubmed \| Lancet Oncol) Manual	Phase 3	Prostatic Cancer	-	Padeliporfin	xqkhyarxsn(rwhxndcdhg) = rbluzdgmet opgjpgeuje (xayptebefu ) View more	Positive	01 Feb 2017
NCT01310894 (CLIN1001 PCM301, Pubmed \| Lancet Oncol) Manual	Phase 3	Prostatic Cancer	-	active surveillance	xqkhyarxsn(rwhxndcdhg) = fxvpetscif opgjpgeuje (xayptebefu ) View more	Positive	01 Feb 2017
NCT00946881 (Pubmed \| J Urol)	Phase 1/2	Prostatic Cancer	30	WST11 vascular targeted photodynamic therapy	emkbciixbf(jbykdeqfus) = jbsnpioaxz diumxnmylb (xsuswqypix )	-	01 Oct 2016
MP59-03 (AUA2014)	Not Applicable	-	16	WST-11 VTP	bjkuvnpvlx(wuemcedyzr) = Chronic ablations showed the development of cortical fibrosis qkzyehopqy (vvekpjyxzs ) View more	-	01 Apr 2014

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis